This report was first published by Endpoints News. To see the original version, click here
Isomorphic Labs said Tuesday it had closed a $2.1 billion Series B round, cementing its bellwether role in using AI for drug discovery.
For privately held companies, Isomorphic’s raise is the second-largest in biotech history, surpassed only by Altos Labs’ $3 billion debut in 2022. Isomorphic was founded in 2021 out of Google DeepMind to remake drug R&D by advancing beyond the firm’s Nobel Prize-winning AI methods like AlphaFold. The London-based company raised $600 million last year in its first external funding outside of Google.
您已阅读9%（626字），剩余91%（6519字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。